Novo Nordisk Faces a Summer of Dual Catalysts as Oral Wegovy and Medicare Converge

The Danish pharma giant is steering into a pivotal second half of 2026, with two powerful demand drivers colliding against persistent pricing headwinds. On July 1, Medicare beneficiaries in the US gain subsidised access to Wegovy injections — a pool of roughly ten percent of eligible seniors — with monthly copays slashed to just $50. That shift alone could unlock millions of new patients for Novo Nordisk’s flagship weight-loss franchise. At the same time, the company’s oral Wegovy tablet has already racked up more than three million prescriptions in its first five months on the market, drawing almost exclusively first-time GLP-1 users and sidestepping the feared cannibalisation of the injectable business.

The tablet’s rollout has been nothing short of explosive — a prescription every five seconds over that five-month window, according to data disclosed at the American Diabetes Association meeting in June. The European Medicines Agency’s CHMP has now issued a positive opinion for EU approval, which would make it the first oral GLP-1 therapy for weight loss on the continent, complete with cardiovascular data from the SELECT trial in the label. In the UK, where the pill was approved on June 11, commercial distribution is still ramping up; private prescriptions could appear within weeks, though NHS reimbursement awaits a NICE review.

All of this volume growth, however, is unfolding against a severe drop in US net prices. Novo Nordisk guided in early 2026 that full-year revenue and operating profit would decline by 5 to 13 percent at constant exchange rates, a sharp reversal from the 10 percent revenue growth posted in 2025. The culprit is a pricing agreement tied to Trump-era most-favoured-nation policy, which forced steep discounts on semaglutide products. First-quarter US adjusted sales fell 11 percent on a currency-neutral basis, and volume gains only partially offset the damage. The critical question for the Q2 report, due August 5, is whether the tablet and the Medicare tailwind can together close the revenue gap left by price erosion.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The company is also shoring up confidence with a hefty share buyback. Up to 15 billion Danish kroner are being deployed through February 2027, and by mid-June Novo had already repurchased nearly 20 million B-shares, equivalent to roughly one percent of its outstanding equity.

Yet the competitive landscape is intensifying. Eli Lilly won US approval for its own oral GLP-1, Foundayo (orforglipron), on April 1. As a small molecule, it is cheaper and easier to manufacture than peptide-based semaglutide, and Lilly has submitted it for approval in more than 40 countries. On the injectable front, Novo’s combination therapy CagriSema — filed with the FDA in December 2025 — posted a 23.0 percent weight reduction after 84 weeks in the REDEFINE 4 head-to-head study, falling short of the 25 percent target and trailing Lilly’s tirzepatide at 25.5 percent. That disappointment has left the market sceptical, though a separate REDEFINE 1 trial showed 91.9 percent of participants achieving at least 5 percent weight loss, well above placebo. The FDA decision on CagriSema is anticipated by year-end.

With the stock trading at €41.76, it has recovered roughly 9 percent over the past month but remains nearly 32 percent below the 52-week high of €61.20. The relative strength index sits at 69.8, flirting with overbought territory after the sharp bounce from its March low. The 200-day moving average at €40.96 offers immediate support, while the 50-day line at €37.65 sits about 11 percent lower.

The August 5 update will be the first real test of whether the new-patient effect from the oral Wegovy and the Medicare opening can sustain the rally. If the data show that prescription volumes are translating into durable revenue — and that patient adherence holds up — the bull case gains a powerful anchor. But if the price erosion continues to outpace volume growth, or if early signals point to weaker persistence on the tablet, the stock could easily retest the 50-day average. The second binary moment arrives late this year with the CagriSema verdict, which will either differentiate Novo’s pipeline or deepen the bearish narrative.

Ad

Novo Nordisk Stock: New Analysis - 26 June

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69629459 |